PUBLICATION OF PROSPECTUS FROM SCN

(NGM:SCN)

On May 12, 2008, an Extraordinary General Meeting in Scandinavian Clinical Nutrition i Sverige AB (publ) decided to increase the company’s share capital through a rights issue. From today, May 20, 2008, the prospectus describing the terms in the rights issue is available for shareholders and the public. The rights issue is 100 percent guaranteed by shareholders and industrial investors.

The prospectus will be distributed to the company’s shareholders with known address starting on May 26, 2008. It will also be available on the company’s website www.scnutrition.com, and can be ordered from the company by phone +46 8 586 107 80. The prospectus is also kept available at the company’s head office, with address Strandvägen 7A, 114 56, Stockholm, SWEDEN.

The rights issue is carried out as follows:

• For each held share as of May 19, 2008, one (1) unit right is received

• Twelve (12) unit rights entitles to subscription of one (1) Unit

• One (1) Unit consists of one (1) new share à SEK 10.00 and one (1) convertible bond à nominal value SEK 20.00. One (1) convertible bond entitles the call for conversion to one (1) new share. The conversion price shall be SEK 20.00

• The subscription price is SEK 30.00 per Unit

• The subscription period is May 28 – June 12, 2008

• Trading in unit rights takes place on NGM Equity and Oslo Axess May 28 – June 9, 2008

• Trading in BTU takes place on NGM Equity from May 28, 2008 until the issue is registered at the Swedish Companies Registration Office

• The convertible bonds will be listed on NGM Equity with trading estimated to commence by the end of July, 2008

The new issue of approximately MSEK 37 is guaranteed to 100 percent by a consortium consisting of Ulf Söderberg via the company US i Ljungå Förvaltnings AB, Carsten Waern via the company Pharmavie Consult AS, Escudeira AG, Handinter Gamma AG, Handinter Kappa AG, Kurt Schalling, TCAW Förvaltning AB, Creative Arts SA, JC & Associates AB and Hurricane Invest AS.

Glitnir Corporate Finance AB is financial advisor in connection with the issue.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Thomas Christensen, CFO, tc@scnutrition.com, +47 922 55 444

Scandinavian Clinical Nutrition AB (publ) works in R&D and sales of scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina and Ledactin. Core competence and strategic alliances within both R&D and sales, in combination with innovative and scientifically documented products, create the right conditions for profitable growth on the international market. The shares of SCN are traded under the ticker "SCN" on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se).